Recent trends in antibody-based oncologic imaging

Cancer Letters

Volumn 315, Issue 2, 2012, Pages 97-111

  Kaur, Sukhwinder ^a   Venktaraman, Ganesh ^a   Jain, Maneesh ^a   Senapati, Shantibhusan ^a   Garg, Pradeep K ^c   Batra, Surinder K ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

Antibody; Imaging; Optical; SPECT; Tumor

Indexed keywords

ANTIBODY; ARCITUMOMAB TC 99M; BECTUMOMAB; CAPROMAB PENDETIDE IN 111; CD19 ANTIBODY; CD3 ANTIBODY; CONTRAST MEDIUM; COPPER 64; FLUORINE 18; GALLIUM 68; HUMASPECT TC; IBRITUMOMAB TIUXETAN; IGOVOMAB; IMCIROMAB PENTETATE; IODINE 124; IORC 5; L 19; MONOCLONAL ANTIBODY; NIMOTUZUMAB; NOFETUMOMAB MERPENTAN TC 99M; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; ONCOSCINT; PENTETATE INDIUM IN 111; RITUXIMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TOSITUMOMAB I 131; TRACER; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOTUMUMAB;

ANTIGEN BINDING; CANCER DIAGNOSIS; DIAGNOSTIC IMAGING; DRUG CLEARANCE; ECHOGRAPHY; MICROBUBBLE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; ONCOLOGIC IMAGING; OPTICAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RAMAN SPECTROMETRY; SHORT SURVEY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE;

EID: 84355162011     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.10.017     Document Type: Review

References (123)

1. Blasberg R.G. Imaging update: new windows, new views. Clin. Cancer Res. 2007, 13:3444-3448.
2. van Dongen G.A., Visser G.W., Lub-De Hooge M.N., de Vries E.G., Perk L.R. Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist 2007, 12:1379-1389.
3. Spanoudaki V.C., Ziegler S.I. PET & SPECT instrumentation. Handb. Exp. Pharmacol. 2008, 53-74.
4. Goldenberg D.M., Chatal J.F., Barbet J., Boerman O., Sharkey R.M. Cancer imaging and therapy with bispecific antibody pretargeting, update. Cancer Ther. 2007, 2:19-31.
5. Kelloff G.J., Krohn K.A., Larson S.M., Weissleder R., Mankoff D.A., Hoffman J.M., Link J.M., Guyton K.Z., Eckelman W.C., Scher H.I., O'Shaughnessy J., Cheson B.D., Sigman C.C., Tatum J.L., Mills G.Q., Sullivan D.C., Woodcock J. The progress and promise of molecular imaging probes in oncologic drug development. Clin. Cancer Res. 2005, 11:7967-7985.
6. Brassell S.A., Rosner I.L., McLeod D.G. Update on magnetic resonance imaging, ProstaScint, and novel imaging in prostate cancer. Curr. Opin. Urol. 2005, 15:163-166.
7. Keane T.E., Rosner I.L., Wingo M.S., McLeod D.G. The emergence of radioimmunoscintigraphy for prostate cancer. Rev. Urol. 2006, 8(Suppl 1:S20-8):S20-S28.
8. Kimura M., Tsivian M., Mouraviev V., Mayes J.M., Price M.M., Bannister M.C., Madden J.F., Wong T.Z., Polascik T.J. Utilization of (111)In-Capromab pendetide SPECT-CT for detecting seminal vesicle invasion with recurrent prostate cancer after primary in situ therapy. Int. J. Urol. 2009, 16:971-975.
9. Seo Y., Aparici C.M., Cooperberg M.R., Konety B.R., Hawkins R.A. In vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CT. J. Nucl. Med. 2010, 51:31-36.
10. Mitra D., Brumlik M.J., Okamgba S.U., Zhu Y., Duplessis T.T., Parvani J.G., Lesko S.M., Brogi E., Jones F.E. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol. Cancer Ther. 2009, 8:2152-2162.
11. Barros F.F., Powe D.G., Ellis I.O., Green A.R. Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments. Histopathology 2010, 56:560-572.
12. Lub-De Hooge M.N., Kosterink J.G., Perik P.J., Nijnuis H., Tran L., Bart J., Suurmeijer A.J., de J.S., Jager P.L., de Vries E.G. Preclinical characterisation of 111In-DTPA-trastuzumab. Br. J. Pharmacol. 2004, 143:99-106.
13. Dijkers E.C., Oude Munnink T.H., Kosterink J.G., Brouwers A.H., Jager P.L., de J., van Dongen G.A., Schroder C.P., Lub-De Hooge M.N., de Vries E.G. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin. Pharmacol. Ther. 2010, 87:586-592.
14. Granowska M., Britton K.E., Mather S.J., Lowe D.G., Ellison D., Bomanji J., Burchell J., Taylor-Papadimitriou J., Hudson C.R., Shepherd J.H. Radioimmunoscintigraphy with technetium-99m-labelled monoclonal antibody, SM3, in gynaecological cancer. Eur. J. Nucl. Med. 1993, 20:483-489.
15. Biassoni L., Granowska M., Carroll M.J., Mather S.J., Howell R., Ellison D., MacNeill F.A., Wells C.A., Carpenter R., Britton K.E. 99mTc-labelled SM3 in the preoperative evaluation of axillary lymph nodes and primary breast cancer with change detection statistical processing as an aid to tumour detection. Br. J. Cancer 1998, 77:131-138.
16. Al-Yasi A.R., Carroll M.J., Ellison D., Granowska M., Mather S.J., Wells C.A., Carpenter R., Britton K.E. Axillary node status in breast cancer patients prior to surgery by imaging with Tc-99m humanised anti-PEM monoclonal antibody, hHMFG1. Br. J. Cancer. 2002, 86:870-878.
17. Granowska M., Mather S.J., Britton K.E., Bentley S., Richman P., Phillips R.K., Northover J.M. 99mTc radioimmunoscintigraphy of colorectal cancer. Br. J. Cancer 1990, 52(Suppl. 10:30-3):30-33.
18. Lunniss P.J., Skinner S., Britton K.E., Granowska M., Morris G., Northover J.M. Effect of radioimmunoscintigraphy on the management of recurrent colorectal cancer. Br. J. Surg. 1999, 86:244-249.
19. Kim J.C., Kim W.S., Ryu J.S., Oh S.J., Lee D.H., Koo K.H., Roh S.A., Kim H.C., Yu C.S., Kang G.H., Bodmer W.F. Applicability of carcinoembryonic antigen-specific monoclonal antibodies to radioimmunoguided surgery for human colorectal carcinoma. Cancer Res. 2000, 60:4825-4829.
20. Kim J.C., Roh S.A., Koo K.H., Ryu J.H., Hong H.K., Oh S.J., Ryu J.S., Kim H.J., Bodmer W.F. Enhancement of colorectal tumor targeting using a novel biparatopic monoclonal antibody against carcinoembryonic antigen in experimental radioimmunoguided surgery. Int. J. Cancer 2002, 97:542-547.
21. Kim J.C., Roh S.A., Koo K.H., Cho Y.K., Kim H.C., Yu C.S., Oh S.J., Ryu J.S., Bicknell D.C., Bodmer W.F. Preclinical application of radioimmunoguided surgery using anti-carcinoembryonic antigen biparatopic antibody in the colon cancer. Eur. Surg. Res. 2005, 37:36-44.
22. Verel I., Visser G.W., van Dongen G.A. The promise of immuno-PET in radioimmunotherapy. J. Nucl. Med. 2005, 46(Suppl 1:164S-71S):164S-171S.
23. Avril N., Rose C.A., Schelling M., Dose J., Kuhn W., Bense S., Weber W., Ziegler S., Graeff H., Schwaiger M. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J. Clin. Oncol. 2000, 18:3495-3502.
24. Cai W. PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J. Nucl. Med. 2007, 48:304-310.
25. Sundaresan G., Yazaki P.J., Shively J.E., Finn R.D., Larson S.M., Raubitschek A.A., Williams L.E., Chatziioannou A.F., Gambhir S.S., Wu A.M. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J. Nucl. Med. 2003, 44:1962-1969.
26. Kenanova V., Olafsen T., Crow D.M., Sundaresan G., Subbarayan M., Carter N.H., Ikle D.N., Yazaki P.J., Chatziioannou A.F., Gambhir S.S., Williams L.E., Shively J.E., Colcher D., Raubitschek A.A., Wu A.M. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res. 2005, 65:622-631.
27. Divgi C.R., Pandit-Taskar N., Jungbluth A.A., Reuter V.E., Gonen M., Ruan S., Pierre C., Nagel A., Pryma D.A., Humm J., Larson S.M., Old L.J., Russo P. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007, 8:304-310.
28. Borsi L., Balza E., Bestagno M., Castellani P., Carnemolla B., Biro A., Leprini A., Sepulveda J., Burrone O., Neri D., Zardi L. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int. J. Cancer 2002, 102:75-85.
29. Tijink B.M., Perk L.R., Budde M., Stigter-van W.M., Visser G.W., Kloet R.W., Dinkelborg L.M., Leemans C.R., Neri D., van Dongen G.A. (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy. Eur. J. Nucl. Med. Mol. Imag. 2009, 36:1235-1244.
30. Verel I., Visser G.W., Boellaard R., Stigter-van W.M., Snow G.B., van Dongen G.A. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J. Nucl. Med. 2003, 44:1271-1281.
31. Verel I., Visser G.W., Vosjan M.J., Finn R., Boellaard R., van Dongen G.A. High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy. Eur. J. Nucl. Med. Mol. Imag. 2004, 31:1645-1652.
32. Verel I., Visser G.W., Boellaard R., Boerman O.C., van E.J., Snow G.B., Lammertsma A.A., van Dongen G.A. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J. Nucl. Med. 2003, 44:1663-1670.
33. Vosjan M.J., Perk L.R., Visser G.W., Budde M., Jurek P., Kiefer G.E., van Dongen G.A. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat. Protoc. 2010, 5:739-743.
34. Zalutsky M.R. Potential of immuno-positron emission tomography for tumor imaging and immunotherapy planning. Clin. Cancer Res. 2006, 12:1958-1960.
35. Borjesson P.K., Jauw Y.W., Boellaard R., de B.R., Comans E.F., Roos J.C., Castelijns J.A., Vosjan M.J., Kummer J.A., Leemans C.R., Lammertsma A.A., van Dongen G.A. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin. Cancer Res. 2006, 12:2133-2140.
36. Dijkers E.C., Kosterink J.G., Rademaker A.P., Perk L.R., van Dongen G.A., Bart J., de J., de Vries E.G., Lub-De Hooge M.N. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J. Nucl. Med. 2009, 50:974-981.
37. Brouwers A., Verel I., van E.J., Visser G., Steffens M., Oosterwijk E., Corstens F., Oyen W., Van D.G., Boerman O. PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer Biother. Radiopharm. 2004, 19:155-163.
38. Perk L.R., Stigter-van W.M., Visser G.W., Kloet R.W., Vosjan M.J., Leemans C.R., Giaccone G., Albano R., Comoglio P.M., van Dongen G.A. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur. J. Nucl. Med. Mol. Imag. 2008, 35:1857-1867.
39. Wu A.M., Yazaki P.J., Tsai S., Nguyen K., Anderson A.L., McCarthy D.W., Welch M.J., Shively J.E., Williams L.E., Raubitschek A.A., Wong J.Y., Toyokuni T., Phelps M.E., Gambhir S.S. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:8495-8500.
40. Olafsen T., Tan G.J., Cheung C.W., Yazaki P.J., Park J.M., Shively J.E., Williams L.E., Raubitschek A.A., Press M.F., Wu A.M. Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng. Des. Sel. 2004, 17:315-323.
41. Olafsen T., Kenanova V.E., Sundaresan G., Anderson A.L., Crow D., Yazaki P.J., Li L., Press M.F., Gambhir S.S., Williams L.E., Wong J.Y., Raubitschek A.A., Shively J.E., Wu A.M. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res. 2005, 65:5907-5916.
42. Schuhmacher J., Kaul S., Klivenyi G., Junkermann H., Magener A., Henze M., Doll J., Haberkorn U., Amelung F., Bastert G. Immunoscintigraphy with positron emission tomography: gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies. Cancer Res. 2001, 61:3712-3717.
43. Smith-Jones P.M., Solit D.B., Akhurst T., Afroze F., Rosen N., Larson S.M. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat. Biotechnol. 2004, 22:701-706.
44. Schoffelen R., Sharkey R.M., Goldenberg D.M., Franssen G., McBride W.J., Rossi E.A., Chang C.H., Laverman P., Disselhorst J.A., Eek A., van der Graaf W.T., Oyen W.J., Boerman O.C. Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts. Mol. Cancer Ther. 2010, 9:1019-1027.
45. Robinson M.K., Doss M., Shaller C., Narayanan D., Marks J.D., Adler L.P., Gonzalez Trotter D.E., Adams G.P. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res. 2005, 65:1471-1478.
46. Hasegawa B.H., Wong K.H., Iwata K., Barber W.C., Hwang A.B., Sakdinawat A.E., Ramaswamy M., Price D.C., Hawkins R.A. Dual-modality imaging of cancer with SPECT/CT. Technol. Cancer Res. Treat. 2002, 1:449-458.
47. Paudyal P., Paudyal B., Iida Y., Oriuchi N., Hanaoka H., Tominaga H., Ishikita T., Yoshioka H., Higuchi T., Endo K. Dual functional molecular imaging probe targeting CD20 with PET and optical imaging. Oncol. Rep. 2009, 22:115-119.
48. Vaneycken I., Devoogdt N., Van G.N., Vincke C., Xavier C., Wernery U., Muyldermans S., Lahoutte T., Caveliers V. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J. 2011, 25:2433-2446.
49. Gainkam L.O., Huang L., Caveliers V., Keyaerts M., Hernot S., Vaneycken I., Vanhove C., Revets H., De B.P., Lahoutte T. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J. Nucl. Med. 2008, 49:788-795.
50. Hoppmann S., Miao Z., Liu S., Liu H., Ren G., Bao A., Cheng Z. Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting. Bioconjug. Chem. 2011, 22:413-421.
51. Kramer-Marek G., Kiesewetter D.O., Capala J. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules. J. Nucl. Med. 2009, 50:1131-1139.
52. Penuelas I., Haberkorn U., Yaghoubi S., Gambhir S.S. Gene therapy imaging in patients for oncological applications. Eur. J. Nucl. Med. Mol. Imag. 2005, 32(Suppl 2:S384-403):S384-S403.
53. Venisnik K.M., Olafsen T., Loening A.M., Iyer M., Gambhir S.S., Wu A.M. Bifunctional antibody-Renilla luciferase fusion protein for in vivo optical detection of tumors. Protein Eng. Des. Sel. 2006, 19:453-460.
54. Koyama Y., Hama Y., Urano Y., Nguyen D.M., Choyke P.L., Kobayashi H. Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu. Clin. Cancer Res. 2007, 13:2936-2945.
55. Hama Y., Urano Y., Koyama Y., Kamiya M., Bernardo M., Paik R.S., Shin I.S., Paik C.H., Choyke P.L., Kobayashi H. A target cell-specific activatable fluorescence probe for in vivo molecular imaging of cancer based on a self-quenched avidin-rhodamine conjugate. Cancer Res. 2007, 67:2791-2799.
56. Bremer C., Bredow S., Mahmood U., Weissleder R., Tung C.H. Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. Radiology 2001, 221:523-529.
57. Mahmood U., Tung C.H., Bogdanov A., Weissleder R. Near-infrared optical imaging of protease activity for tumor detection. Radiology 1999, 213:866-870.
58. Ogawa M., Kosaka N., Longmire M.R., Urano Y., Choyke P.L., Kobayashi H. Fluorophore-quencher based activatable targeted optical probes for detecting in vivo cancer metastases. Mol. Pharm. 2009, 6:386-395.
59. Ogawa M., Kosaka N., Choyke P.L., Kobayashi H. In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res. 2009, 69:1268-1272.
60. He X., Wang K., Cheng Z. In vivo near-infrared fluorescence imaging of cancer with nanoparticle-based probes. Wiley. Interdiscip. Rev. Nanomed. Nanobiotechnol. 2010, 2:349-366.
61. Wang K., Wang K., Li W., Huang T., Li R., Wang D., Shen B., Chen X. Characterizing breast cancer xenograft epidermal growth factor receptor expression by using near-infrared optical imaging. Acta Radiol. 2009, 50:1095-1103.
62. Rosenthal E.L., Kulbersh B.D., Duncan R.D., Zhang W., Magnuson J.S., Carroll W.R., Zinn K. In vivo detection of head and neck cancer orthotopic xenografts by immunofluorescence. Laryngoscope 2006, 116:1636-1641.
63. Kampmeier F., Niesen J., Koers A., Ribbert M., Brecht A., Fischer R., Kiessling F., Barth S., Thepen T. Rapid optical imaging of EGF receptor expression with a single-chain antibody SNAP-tag fusion protein. Eur. J. Nucl. Med. Mol. Imag. 2010, 37:1926-1934.
64. Montet X., Ntziachristos V., Grimm J., Weissleder R. Tomographic fluorescence mapping of tumor targets. Cancer Res. 2005, 65:6330-6336.
65. Bogdanov A.A., Lin C.P., Kang H.W. Optical imaging of the adoptive transfer of human endothelial cells in mice using anti-human CD31 monoclonal antibody. Pharm. Res. 2007, 24:1186-1192.
66. Zou P., Xu S., Povoski S.P., Wang A., Johnson M.A., Martin E.W., Subramaniam V., Xu R., Sun D. Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice. Mol. Pharm. 2009, 6:428-440.
67. Alford R., Ogawa M., Hassan M., Gandjbakhche A.H., Choyke P.L., Kobayashi H. Fluorescence lifetime imaging of activatable target specific molecular probes. Contrast. Media Mol. Imag. 2010, 5:1-8.
68. Sampath L., Kwon S., Ke S., Wang W., Schiff R., Mawad M.E., Sevick-Muraca E.M. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J. Nucl. Med. 2007, 48:1501-1510.
69. Drummen G.P. Quantum dots-from synthesis to applications in biomedicine and life sciences. Int. J. Mol. Sci. 2010, 11:154-163.
70. Yang L., Mao H., Wang Y.A., Cao Z., Peng X., Wang X., Duan H., Ni C., Yuan Q., Adams G., Smith M.Q., Wood W.C., Gao X., Nie S. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small 2009, 5:235-243.
71. Gao X., Cui Y., Levenson R.M., Chung L.W., Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol. 2004, 22:969-976.
72. Gonda K., Watanabe T.M., Ohuchi N., Higuchi H. In vivo nano-imaging of membrane dynamics in metastatic tumor cells using quantum dots. J. Biol. Chem. 2010, 285:2750-2757.
73. Barat B., Sirk S.J., McCabe K.E., Li J., Lepin E.J., Remenyi R., Koh A.L., Olafsen T., Gambhir S.S., Weiss S., Wu A.M. Cys-diabody quantum dot conjugates (immunoQdots) for cancer marker detection. Bioconjug. Chem. 2009, 20:1474-1481.
74. Chen L.D., Liu J., Yu X.F., He M., Pei X.F., Tang Z.Y., Wang Q.Q., Pang D.W., Li Y. The biocompatibility of quantum dot probes used for the targeted imaging of hepatocellular carcinoma metastasis. Biomaterials 2008, 29:4170-4176.
75. Choi H.S., Liu W., Misra P., Tanaka E., Zimmer J.P., Itty I.B., Bawendi M.G., Frangioni J.V. Renal clearance of quantum dots. Nat. Biotechnol. 2007, 25:1165-1170.
76. Ballou B., Lagerholm B.C., Ernst L.A., Bruchez M.P., Waggoner A.S. Noninvasive imaging of quantum dots in mice. Bioconjug. Chem. 2004, 15:79-86.
77. Dijkmans P.A., Juffermans L.J., Musters R.J., van W.A., ten Cate F.J., van G.W., Visser C.A., de J.N., Kamp O. Microbubbles and ultrasound: from diagnosis to therapy. Eur. J. Echocardiogr. 2004, 5:245-256.
78. Lindner J.R. Microbubbles in medical imaging: current applications and future directions. Nat. Rev. Drug Discov. 2004, 3:527-532.
79. Kiessling F. Science to practice: the dawn of molecular US imaging for clinical cancer imaging. Radiology 2010, 256:331-333.
80. Bachmann C., Klibanov A.L., Olson T.S., Sonnenschein J.R., Rivera-Nieves J., Cominelli F., Ley K.F., Lindner J.R., Pizarro T.T. Targeting mucosal addressin cellular adhesion molecule (MAdCAM)-1 to noninvasively image experimental Crohn's disease. Gastroenterology 2006, 130:8-16.
81. Lindner J.R., Song J., Christiansen J., Klibanov A.L., Xu F., Ley K. Ultrasound assessment of inflammation and renal tissue injury with microbubbles targeted to P-selectin. Circulation 2001, 104:2107-2112.
82. Weller G.E., Lu E., Csikari M.M., Klibanov A.L., Fischer D., Wagner W.R., Villanueva F.S. Ultrasound imaging of acute cardiac transplant rejection with microbubbles targeted to intercellular adhesion molecule-1. Circulation 2003, 108:218-224.
83. Unger E.C., McCreery T.P., Sweitzer R.H., Shen D., Wu G. In vitro studies of a new thrombus-specific ultrasound contrast agent. Am. J. Cardiol. 1998, 81:58G-61G.
84. Lanza G.M., Wallace K.D., Scott M.J., Cacheris W.P., Abendschein D.R., Christy D.H., Sharkey A.M., Miller J.G., Gaffney P.J., Wickline S.A. A novel site-targeted ultrasonic contrast agent with broad biomedical application. Circulation 1996, 94:3334-3340.
85. Willmann J.K., Cheng Z., Davis C., Lutz A.M., Schipper M.L., Nielsen C.H., Gambhir S.S. Targeted microbubbles for imaging tumor angiogenesis: assessment of whole-body biodistribution with dynamic micro-PET in mice. Radiology 2008, 249:212-219.
86. Ferrante E.A., Pickard J.E., Rychak J., Klibanov A., Ley K. Dual targeting improves microbubble contrast agent adhesion to VCAM-1 and P-selectin under flow. J. Control Release 2009, 140:100-107.
87. Dayton P.A., Pearson D., Clark J., Simon S., Schumann P.A., Zutshi R., Matsunaga T.O., Ferrara K.W. Ultrasonic analysis of peptide- and antibody-targeted microbubble contrast agents for molecular imaging of alphavbeta3-expressing cells. Mol. Imag. 2004, 3:125-134.
88. Leong-Poi H., Christiansen J., Klibanov A.L., Kaul S., Lindner J.R. Noninvasive assessment of angiogenesis by ultrasound and microbubbles targeted to alpha(v)-integrins. Circulation 2003, 107:455-460.
89. Liu F., Wang X., Yang L., Jiang B. A novel method for preparing microbubbles targeting hepatocellular carcinoma. Hepatogastroenterology 2009, 56:1163-1168.
90. Curtet C., Maton F., Havet T., Slinkin M., Mishra A., Chatal J.F., Muller R.N. Polylysine-Gd-DTPAn and polylysine-Gd-DOTAn coupled to anti-CEA F(ab')2 fragments as potential immunocontrast agents. Relaxometry, biodistribution, and magnetic resonance imaging in nude mice grafted with human colorectal carcinoma. Invest Radiol. 1998, 33:752-761.
91. Shahbazi-Gahrouei D., Williams M., Rizvi S., Allen B.J. In vivo studies of Gd-DTPA-monoclonal antibody and gd-porphyrins: potential magnetic resonance imaging contrast agents for melanoma. J. Magn Reson. Imag. 2001, 14:169-174.
92. Kuriu Y., Otsuji E., Kin S., Nakase Y., Fukuda K., Okamoto K., Hagiwara A., Yamagishi H. Monoclonal antibody conjugated to gadolinium as a contrast agent for magnetic resonance imaging of human rectal carcinoma. J. Surg. Oncol. 2006, 94:144-148.
93. Artemov D., Mori N., Ravi R., Bhujwalla Z.M. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res. 2003, 63:2723-2727.
94. Zhu W., Okollie B., Bhujwalla Z.M., Artemov D. PAMAM dendrimer-based contrast agents for MR imaging of Her-2/neu receptors by a three-step pretargeting approach. Magn Reson. Med. 2008, 59:679-685.
95. Zhang D., Feng X.Y., Henning T.D., Wen L., Lu W.Y., Pan H., Wu X., Zou L.G. MR imaging of tumor angiogenesis using sterically stabilized Gd-DTPA liposomes targeted to CD105. Eur. J. Radiol. 2009, 70:180-189.
96. Gohr-Rosenthal S., Schmitt-Willich H., Ebert W., Conrad J. The demonstration of human tumors on nude mice using gadolinium-labelled monoclonal antibodies for magnetic resonance imaging. Invest Radiol. 1993, 28:789-795.
97. Remsen L.G., McCormick C.I., Roman-Goldstein S., Nilaver G., Weissleder R., Bogdanov A., Hellstrom I., Kroll R.A., Neuwelt E.A. MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosis. AJNR Am. J. Neuroradiol. 1996, 17:411-418.
98. Liu P., Li Z., Zhu M., Sun Y., Li Y., Wang H., Duan Y. Preparation of EGFR monoclonal antibody conjugated nanoparticles and targeting to hepatocellular carcinoma. J. Mater. Sci. Mater. Med. 2010, 21:551-556.
99. Toma A., Otsuji E., Kuriu Y., Okamoto K., Ichikawa D., Hagiwara A., Ito H., Nishimura T., Yamagishi H. Monoclonal antibody A7-superparamagnetic iron oxide as contrast agent of MR imaging of rectal carcinoma. Br. J. Cancer. 2005, 93:131-136.
100. Baio G., Fabbi M., Salvi S., de T.D., Truini M., Ferrini S., Neumaier C.E. Two-step in vivo tumor targeting by biotin-conjugated antibodies and superparamagnetic nanoparticles assessed by magnetic resonance imaging at 1.5 T. Mol. Imag. Biol. 2010, 12:305-315.
101. Chen T.J., Cheng T.H., Chen C.Y., Hsu S.C., Cheng T.L., Liu G.C., Wang Y.M. Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI. J. Biol. Inorg. Chem. 2009, 14:253-260.
102. Loo C., Lowery A., Halas N., West J., Drezek R. Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano. Lett. 2005, 5:709-711.
103. Elbayoumi T.A., Torchilin V.P. Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies. Eur. J. Nucl. Med. Mol. Imag. 2006, 33:1196-1205.
104. Erdogan S., Roby A., Sawant R., Hurley J., Torchilin V.P. Gadolinium-loaded polychelating polymer-containing cancer cell-specific immunoliposomes. J. Liposome Res. 2006, 16:45-55.
105. Lu W., Arumugam S.R., Senapati D., Singh A.K., Arbneshi T., Khan S.A., Yu H., Ray P.C. Multifunctional oval-shaped gold-nanoparticle-based selective detection of breast cancer cells using simple colorimetric and highly sensitive two-photon scattering assay. ACS Nano. 2010, 4:1739-1749.
106. Kim C.S., Wilder-Smith P., Ahn Y.C., Liaw L.H., Chen Z., Kwon Y.J. Enhanced detection of early-stage oral cancer in vivo by optical coherence tomography using multimodal delivery of gold nanoparticles. J. Biomed. Opt. 2009, 14:034008.
107. Niu Z., Fang Y. Surface-enhanced Raman scattering of single-walled carbon nanotubes on silver-coated and gold-coated filter paper. J. Colloid Interface Sci. 2006, 303:224-228.
108. Nie S., Emory S.R. Probing single molecules and single nanoparticles by Surface-Enhanced Raman Scattering. Science 1997, 275:1102-1106.
109. Zavaleta C.L., Smith B.R., Walton I., Doering W., Davis G., Shojaei B., Natan M.J., Gambhir S.S. Multiplexed imaging of surface enhanced Raman scattering nanotags in living mice using noninvasive Raman spectroscopy. Proc. Natl. Acad. Sci. U. S. A 2009, 106:13511-13516.
110. Perik P.J., Lub-De Hooge M.N., Gietema J.A., van der Graaf W.T., de Korte M.A., Jonkman S., Kosterink J.G., van Veldhuisen D.J., Sleijfer D.T., Jager P.L., de Vries E.G. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J. Clin. Oncol. 2006, 24:2276-2282.
111. Gmeiner S.T., Fettich J., Zver S., Mlinaric-Rascan I., Hojker S., Socan A., Peitl P.K., Mather S. 99mTc-labelled rituximab, a new non-Hodgkin's lymphoma imaging agent: first clinical experience. Nucl. Med. Commun. 2008, 29:1059-1065.
112. Birchler M.T., Thuerl C., Schmid D., Neri D., Waibel R., Schubiger A., Stoeckli S.J., Schmid S., Goerres G.W. Immunoscintigraphy of patients with head and neck carcinomas, with an anti-angiogenetic antibody fragment. Otolaryngol. Head Neck Surg. 2007, 136:543-548.
113. Ramos-Suzarte M., Pintado A.P., Mesa N.R., Oliva J.P., Iznaga-Escobar N., Aroche L.T., Pimentel G., Gonzalez J., Cordero M., Rodriguezi O.T., Crombet R.T., Perez R.R. Diagnostic efficacy and safety of 99mtc-labeled monoclonal antibody ior c5 in patients with colorectal and anal carcinomas: final report clinical trial phase I/II. Cancer Biol. Ther. 2007, 6:22-29.
114. Torres L.A., Perera A., Batista J.F., Hernandez A., Crombet T., Ramos M., Neninger E., Perez M., Sanchez E.L., Romero S., Aguilar V., Coca M.A., Iznaga-Escobar N. Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin. Nucl. Med. Commun. 2005, 26:1049-1057.
115. Vaidyanathan G., Jestin E., Olafsen T., Wu A.M., Zalutsky M.R. Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK. Nucl. Med. Biol. 2009, 36:671-680.
116. McBride W.J., Zanzonico P., Sharkey R.M., Noren C., Karacay H., Rossi E.A., Losman M.J., Brard P.Y., Chang C.H., Larson S.M., Goldenberg D.M. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide. J. Nucl. Med. 2006, 47:1678-1688.
117. Lewis M.R., Wang M., Axworthy D.B., Theodore L.J., Mallet R.W., Fritzberg A.R., Welch M.J., Anderson C.J. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy. J. Nucl. Med. 2003, 44:1284-1292.
118. Jun H.Y., Yin H.H., Kim S.H., Park S.H., Kim H.S., Yoon K.H. Visualization of tumor angiogenesis using MR imaging contrast agent Gd-DTPA-anti-VEGF receptor 2 antibody conjugate in a mouse tumor model. Korean J. Radiol. 2010, 11:449-456.
119. Tiefenauer L.X., Tschirky A., Kuhne G., Andres R.Y. In vivo evaluation of magnetite nanoparticles for use as a tumor contrast agent in MRI. Magn Reson. Imag. 1996, 14:391-402.
120. Artemov D., Mori N., Okollie B., Bhujwalla Z.M. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson. Med. 2003, 49:403-408.
121. Huh Y.M., Jun Y.W., Song H.T., Kim S., Choi J.S., Lee J.H., Yoon S., Kim K.S., Shin J.S., Suh J.S., Cheon J. In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. J. Am. Chem. Soc. 2005, 127:12387-12391.
122. Serda R.E., Adolphi N.L., Bisoffi M., Sillerud L.O. Targeting and cellular trafficking of magnetic nanoparticles for prostate cancer imaging. Mol. Imag. 2007, 6:277-288.
123. Funovics M.A., Kapeller B., Hoeller C., Su H.S., Kunstfeld R., Puig S., Macfelda K. MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. Magn Reson. Imag. 2004, 22:843-850.